GlobeNewswire

Chinese visitors can now use Alipay in The Dubai Mall

Dela

Payment now accepted for popular luxury brands, world-class attractions including Dubai Aquarium & Underwater Zoo and At the Top, Burj Khalifa 

HANGZHOU, China and DUBAI, United Arab Emirates, April 25, 2018 (GLOBE NEWSWIRE) -- Alipay, the world's largest online and mobile payment platform operated by Ant Financial Services Group, and The Dubai Mall, the world's largest and most-visited retail and entertainment destination, located in the heart of the prestigious Downtown Dubai, today jointly announced that Chinese mainland visitors can now use Alipay to pay for a wide range of shopping, dining and must-see leisure attractions.

With the remarkable growth and importance of Chinese tourism to Dubai, The Dubai Mall is continuing to look at ways to accommodate their needs, which includes multilingual Guest Services staff and Chinese language Mall Guides.  
Chinese visitors can now look for stores across The Dubai Mall through Alipay's in-app Discover platform, and pay for their orders in RMB via Alipay at the cashiers.

Key destinations include The Souk, an elegantly designed precinct featuring jewellery shops, accessory outlets, traditional Arab clothing and handicraft stores; or The Village, which offers a rich collection of denim brands and brings an outdoor community feel with tree-lined walkways, cafés and restaurants; or the newly expanded Fashion Avenue, which provides a significant boost to Dubai's premium shopping options, with over 150 luxury shopping and dining experiences including flagships and new concepts.

In addition, Chinese visitors can use Alipay at all The Dubai Mall's popular entertainment attractions including Dubai Aquarium & Underwater Zoo, the newly opened VR ParkDubai Ice Rink and At the Top, Burj Khalifa, the world's highest observation deck with an outdoor terrace.

With a total internal floor area of 5.9 million sq ft, The Dubai Mall has 3.77 million sq ft of gross leasable space and over 1,300 retail outlets including two anchor department stores - Galeries Lafayette and Bloomingdale's - and over 200 global food and beverage outlets. The Dubai Mall offers an unparalleled retail mix combined with world-class dining, entertainment and leisure attractions.

The Dubai Mall, the world's largest shopping and entertainment destination, is part of Downtown Dubai, Emaar Properties' flagship mega-development.

Alipay currently has over 520 million active users in China. According to a report from Alipay and Nielsen, ease of payments is also a leading factor when it comes to key purchase decisions for Chinese tourists. 91% of Chinese tourists claimed they would show greater willingness to spend and shop if overseas merchants accepted Chinese mobile payments.

Statistics by The Department of Tourism and Commerce Marketing in Dubai show that over 764,000 Chinese tourists visited Dubai in the fiscal year of 2017, with a year-on-year growth of 41%, ranking China as the 5th largest source market of Dubai. Over 68,000 Chinese tourists visited Dubai this January*. 

Notes to editors
* Details of Chinese tourists visiting Dubai from  Visit Dubai
** Details of Chinese tourists' spending habits from a recent Alipay/Nielsen report (2018)

About Alipay 
Operated by Ant Financial Services Group, Alipay is the world's largest mobile and online payment platform. Launched in 2004, Alipay currently works with over 200 domestic financial institution partners. Over the years, Alipay has evolved from a digital wallet to a lifestyle enabler. Users can hail a taxi, book a hotel, buy movie tickets, pay utility bills, make appointments with doctors, or purchase wealth management products directly from within the app. In addition to online payments, Alipay is expanding to in-store offline payments both inside and outside of China. Over 40 million brick-and-mortar merchants now accept Alipay across China. Alipay's in-store payment service covers over 40 countries and regions across the world, and tax reimbursement via Alipay is supported in 29 countries and regions. Alipay works with over 250 overseas financial institutions and payment solution providers to enable cross-border payments for Chinese travelling overseas and overseas customers who purchase products from Chinese e-commerce sites. Alipay currently supports 27 currencies.

About The Dubai Mall:
Located in the heart of the prestigious Downtown Dubai is The Dubai Mall, the world's largest and most-visited retail and entertainment destination, which welcomed more than 80 million visitors annually. With a total internal floor area of 5.9 million sq ft, The Dubai Mall has 3.77 million sq ft of gross leasable space, over 1,300 retail outlets including two anchor department stores - Galeries Lafayette and Bloomingdale's - and over 200 food and beverage outlets.

The Dubai Mall acts as a gateway for visitors to Burj Khalifa, the global icon. Tickets to At the Top, Burj Khalifa SKY, the world's highest observation deck, are available exclusively to visitors of The Dubai Mall. For more information, visit www.thedubaimall.com or connect with @TheDubaiMall on  Instagram Twitter  &  Facebook

Media Enquiries
For more information on Alipay, please contact:
Xinyun Yang
International Communications
Ant Financial Services Group
Tel: +86 1381 6896 301
Email: xinyun.yang@antfin.com

For more information on The Dubai Mall, please contact:
Nivine William | Rania Moussly 
ASDA'A Burson-Marsteller
+9714 4507 600
nivine.william@bm.com | rania.moussly@bm.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ant Financial Services Group via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum